TY - JOUR
T1 - Incidence and prevalence of nontuberculous mycobacterial lung disease in a Large U.S. Managed Care Health Plan, 2008-2015
AU - Winthrop, Kevin L.
AU - Marras, Theodore K.
AU - Adjemian, Jennifer
AU - Zhang, Haixin
AU - Wang, Ping
AU - Zhang, Quanwu
N1 - Funding Information:
Supported by Insmed Incorporated (Bridgewater, NJ) and in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Publisher Copyright:
© 2020 by the American Thoracic Society.
PY - 2020
Y1 - 2020
N2 - Rationale: Estimating the annual incidence and prevalence of nontuberculous mycobacterial (NTM) lung disease may assist in improving understanding of the public health and economic impacts of this disease and its treatment. Objective: To estimate the yearly incidence and prevalence of administrative claims-based NTM lung disease between 2008 and 2015 in a U.S. managed care claims database. Methods: We used a national managed care claims database (Optum Clinformatics Data Mart) representing a geographically diverse population of approximately 27 million members annually. All medical claims from January 1, 2007, to June 30, 2016, were scanned for diagnosis codes for NTM lung disease (International Classification of Diseases, Ninth Revision, ClinicalModification [ICD-9-CM] code 031.0 or ICD-10-CM code A31.0). We defined a case of NTM lung disease as having at least two medical claims with a code of 031.0 or A31.0 that were dated at least 30 days apart. Annual incidence and prevalence were estimated for each calendar year from 2008 to 2015. Results: From 2008 to 2015, the annual incidence of NTM lung disease increased from 3.13 (95% confidence interval [CI], 2.88-3.40) to 4.73 (95% CI, 4.43-5.05) per 100,000 person-years, and the annual prevalence increased from 6.78 (95% CI, 6.45-7.14) to 11.70 (95% CI, 11.26-12.16) per 100,000 persons. The average annual changes in incidence and prevalence were 15.2% (95% CI, 4.0-6.4%; P,0.01) and 17.5% (95% CI, 6.7-8.2%; P,0.01), respectively. For women, the annual incidence increased from 4.16 (95% CI, 3.76-4.60) to 6.69 (95% CI, 6.19-7.22) per 100,000 person-years, and the annual prevalence increased from 9.63 (95% CI, 9.08-10.22) to 16.78 (95% CI, 16.04-17.55) per 100,000 persons. For individuals aged 65 years or older, the annual incidence increased from 12.70 (95% CI, 11.46-14.07) to 18.37 (95% CI, 16.98-19.87) per 100,000 person-years, and the annual prevalence increased from 30.27 (95% CI, 28.41-32.24) to 47.48 (95% CI, 45.37-49.67) per 100,000 persons. The incidence and prevalence of NTM lung disease increased in most U.S. states and overall at the national level. Conclusions: The incidence and prevalence of NTM lung disease appears to be increasing in the United States, particularly among women and older age groups.
AB - Rationale: Estimating the annual incidence and prevalence of nontuberculous mycobacterial (NTM) lung disease may assist in improving understanding of the public health and economic impacts of this disease and its treatment. Objective: To estimate the yearly incidence and prevalence of administrative claims-based NTM lung disease between 2008 and 2015 in a U.S. managed care claims database. Methods: We used a national managed care claims database (Optum Clinformatics Data Mart) representing a geographically diverse population of approximately 27 million members annually. All medical claims from January 1, 2007, to June 30, 2016, were scanned for diagnosis codes for NTM lung disease (International Classification of Diseases, Ninth Revision, ClinicalModification [ICD-9-CM] code 031.0 or ICD-10-CM code A31.0). We defined a case of NTM lung disease as having at least two medical claims with a code of 031.0 or A31.0 that were dated at least 30 days apart. Annual incidence and prevalence were estimated for each calendar year from 2008 to 2015. Results: From 2008 to 2015, the annual incidence of NTM lung disease increased from 3.13 (95% confidence interval [CI], 2.88-3.40) to 4.73 (95% CI, 4.43-5.05) per 100,000 person-years, and the annual prevalence increased from 6.78 (95% CI, 6.45-7.14) to 11.70 (95% CI, 11.26-12.16) per 100,000 persons. The average annual changes in incidence and prevalence were 15.2% (95% CI, 4.0-6.4%; P,0.01) and 17.5% (95% CI, 6.7-8.2%; P,0.01), respectively. For women, the annual incidence increased from 4.16 (95% CI, 3.76-4.60) to 6.69 (95% CI, 6.19-7.22) per 100,000 person-years, and the annual prevalence increased from 9.63 (95% CI, 9.08-10.22) to 16.78 (95% CI, 16.04-17.55) per 100,000 persons. For individuals aged 65 years or older, the annual incidence increased from 12.70 (95% CI, 11.46-14.07) to 18.37 (95% CI, 16.98-19.87) per 100,000 person-years, and the annual prevalence increased from 30.27 (95% CI, 28.41-32.24) to 47.48 (95% CI, 45.37-49.67) per 100,000 persons. The incidence and prevalence of NTM lung disease increased in most U.S. states and overall at the national level. Conclusions: The incidence and prevalence of NTM lung disease appears to be increasing in the United States, particularly among women and older age groups.
KW - Incidence
KW - Nontuberculous mycobacterial infections
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85078816146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078816146&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.201804-236OC
DO - 10.1513/AnnalsATS.201804-236OC
M3 - Article
C2 - 31830805
AN - SCOPUS:85078816146
SN - 2325-6621
VL - 17
SP - 178
EP - 185
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 2
ER -